Cantor Fitzgerald Reaffirms Neutral Rating for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Cantor Fitzgerald reiterated their neutral rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research note published on Wednesday. Cantor Fitzgerald currently has a $27.00 price target on the stock, down from their prior price target of $31.00.

Other equities research analysts have also issued reports about the stock. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a hold rating to a sell rating and set a $31.05 target price on the stock. in a report on Thursday, June 22nd. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a hold rating to a buy rating in a report on Wednesday, July 5th. Maxim Group reiterated a hold rating and set a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, July 13th. Credit Suisse Group reiterated an outperform rating and set a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Finally, Royal Bank Of Canada reiterated an outperform rating and set a $38.00 target price (down from $42.00) on shares of Teva Pharmaceutical Industries Limited in a report on Monday, May 15th. Three analysts have rated the stock with a sell rating, nineteen have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Hold and an average price target of $37.69.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 17.30 on Wednesday. Teva Pharmaceutical Industries Limited has a one year low of $16.81 and a one year high of $55.39. The stock’s market capitalization is $17.58 billion. The company’s 50-day moving average is $29.64 and its 200 day moving average is $31.56.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.25 earnings per share. Equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Cantor Fitzgerald Reaffirms Neutral Rating for Teva Pharmaceutical Industries Limited (NYSE:TEVA)” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://transcriptdaily.com/2017/08/13/cantor-fitzgerald-reaffirms-neutral-rating-for-teva-pharmaceutical-industries-limited-nyseteva.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be given a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 1.97%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is currently -18.95%.

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. Teachers Advisors LLC purchased a new stake in Teva Pharmaceutical Industries Limited during the fourth quarter valued at approximately $21,946,000. Chevy Chase Trust Holdings Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 3.4% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 6,273 shares of the company’s stock valued at $201,000 after buying an additional 207 shares during the period. Manning & Napier Advisors LLC boosted its stake in Teva Pharmaceutical Industries Limited by 15.0% in the first quarter. Manning & Napier Advisors LLC now owns 96,678 shares of the company’s stock valued at $3,101,000 after buying an additional 12,645 shares during the period. National Pension Service boosted its stake in Teva Pharmaceutical Industries Limited by 8.6% in the first quarter. National Pension Service now owns 732,038 shares of the company’s stock valued at $23,945,000 after buying an additional 57,726 shares during the period. Finally, Bank of Montreal Can boosted its stake in Teva Pharmaceutical Industries Limited by 5.4% in the first quarter. Bank of Montreal Can now owns 638,426 shares of the company’s stock valued at $20,486,000 after buying an additional 32,960 shares during the period. 56.27% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply